antibody

p70 S6 Kinase (p70 S6K)

P1001-37Q

100 ul

monoclonal

domestic rabbit

nonconjugated

5i130(49D7)

p70 S6 Kinase (p70 S6K)

rabbit

Mab

Antibodies

100 ul

5i130(49D7)

IgG

p70 S6 kinase is a mitogen activated Ser/Thr protein kinase that is required for cell growth and G1 cell cycle progression (1,2). p70 S6 kinase phosphorylates the S6 protein of the 40S ribosomal subunit and is involved in translational control of 5' oligopyrimidine tract mRNAs (1). A second isoform, p85 S6 kinase, is derived from the same gene and is identical to p70 S6 kinase except for 23 extra residues at the amino-terminus, which encode a nuclear localizing signal (1). Both isoforms lie on a mitogen activated signaling pathway downstream of phosphoinositide-3 kinase (PI-3K) and the target of rapamycin, FRAP/mTOR, a pathway distinct from the Ras/MAP kinase cascade (1). The activity of p70 S6 kinase is controlled by multiple phosphorylation events located within the catalytic, linker and pseudosubstrate domains (1). Phosphorylation of Thr229 in the catalytic domain and Thr389 in the linker domain are most critical for kinase function (1). Phosphorylation of Thr389, however, most closely correlates with p70 kinase activity in vivo (3). Prior phosphorylation of Thr389 is required for the action of phosphoinositide 3-dependent protein kinase 1 (PDK1) on Thr229 (4,5). Phosphorylation of this site is stimulated by growth factors such as insulin, EGF and FGF, as well as by serum and some G-protein-coupled receptor ligands, and is blocked by wortmannin, LY294002 (PI-3K inhibitor) and rapamycin (FRAP/mTOR inhibitor) (1,6,7). Ser411, Thr421 and Ser424 lie within a Ser-Pro-rich region located in the pseudosubstrate region (1). Phosphorylation at these sites is thought to activate p70 S6 kinase via relief of pseudosubstrate suppression (1,2). Another LY294002 and rapamycin sensitive phosphorylation site, Ser371, is an in vitro substrate for mTOR and correlates well with the activity of a partially rapamycin resistant mutant p70 S6 kinase (8). Applications: Suitable for use in Western Blot, Immunohistochemistry. Other applications not tested. Recommended Dilution: Western Blotting: 1:1000 Immunohistochemistry: (Paraffin) 1:60 Citrate/TBST Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot. Store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Hu Mk Mo Rt

Synthetic peptide corresponding to residues surrounding the N-terminus of human p70 S6 kinase.

Detects endogenous levels of total p70 S6 kinase protein. The antibody also recognizes p85 S6 kinase. Species Crossreactivity: Human Monkey Mouse Rat

Purified

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol.

As reported

Product Type: Mab Isotype: IgG Clone No: 5i130(49D7) Host: rabbit Source: human Concentration: As reported Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol. Purity: Purified Immunogen: Synthetic peptide corresponding to residues surrounding the N-terminus of human p70 S6 kinase. Specificity: Detects endogenous levels of total p70 S6 kinase protein. The antibody also recognizes p85 S6 kinase. Species Crossreactivity: Human Monkey Mouse Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

IHC WB

-20°C

(1) Pullen, N. and Thomas, G. (1997) FEBS Lett. 410, 78–82. (2) Dunfer, A. et al. (1999) Exp. Cell Res. 253, 100–109. (3) Weng, Q.P. et al. (1998) J. Biol. Chem. 273, 16621–16629. (4) Pullen, N. et al. (1998) Science 279, 707–710. (5) Alessi, D. et al. (1998) Curr. Biol. 8, 69–81. (6) Polakiewicz, R.D. et al. (1998) J. Biol. Chem. 273, 23534–23541. (7) Finger, D.C. et al. (2002) Genes Dev. 16, 1472–1487. (8) Saitoh, M. et al. (2002) J. Biol. Chem. 277, 20104–20112. General References: 1. Spieker-Polet H, et al. Proc Natl Acad Sci. 1995 Sep 26;92(20):9348-52. 2. Liguori MJ, et al. Hybridoma. 2001 Jun; 20(3):189-98. 3. G.Cano1, F. Milanezi2, D. Leitao2,3, S. Ricardo2, M.J. Brito1, F. C. Schmitt2-3 1Garcia da Orta Hospital, Almada, Portugal,2 Inst. Molec. Pathology and Immunology of Porto University, Portugal,3 Medical Faculty of Porto university, Portugal Diagn Cytopathol, 2003 Oct; 29(4): 207 -11. 4. L.K. Diaz* and N.Sneige *Department of Pathology,Northwestern University, Chicago,+ Department of Pathology, University of Texas, Huston, Adv Anat Pathol,2005; 12(1), 10-19. 5. Z. Huang1, W. Zhu2, G. Szekeres3, H. Xia1 1Spring Bioscience Corp, Fremont,CA, 2 Epitomics Inc, Burlingame,CA, , 4Histopathology Ltd, Hungary, Appl Immunohistochem Mol Morphol. 2005; 13 (1): 91-95 6. S. Rossi1, E. Orvieto1, S.Chinellato1, A. Furlanetto1, L.Laurino1, F. Facchetti2, AP Dei Tos 2 1Department of Pathology, 2Treviso, Italy; *Brescia, University School of Medicine, Brescia, Italy., Abstract presented at USCAP 2004. Modern Pathology 2004; 17 (suppl 1): 361A 7. M. Blechner, E. Ballesteros, D. Mandich, D. Stevens, R. Cartun, Hartford Hospital, Hartford, CT. Abstract presented at USCAP 2004. Modern Pathology 2004; 17 (suppl 1): 241A 8. W. Cheuk, K.O.Y. Wong, C.S.C. Wong and J.K.C. Chan, Department of Pathology, Queen Elizabeth Hospital, Hong Kong, Am J Surg Path, 2004; 28 (6): 801-807. 9. G.B. Budd, E. Tso, B. Yoder, T. Choueiri, P. Elson, S. Tarr, M. Skacel, R. Tubbs, A. Dawson, D. Hicks, Cleveland Clinic Foundation, Cleveland, OH, Abstract presented at ASCO Annual meeting, June 2004, New Orleans 10. S. M. Tarr, S. Short, K. Hansen, T. Morken, H. Xia, E. Downs-Kelly, R. R. Tubbs, D. G. Hicks, Department of Pathology and Laboratory Medicine. The Cleveland Clinic Foundation, Cleveland, Ohio. Lab Vision Corp., Fremont, Ca., Spring Bioscience Corp, Fremont ,CA, Abstract presented at Association for Molecular Pathology meeting, Los Angeles, 2004 11. A.M. Gown, T.S. Barry, P. Kandalaft, L.C. Goldstein, C.C. Tse and D.O. Treaba, Clinical Research Division , PhenoPath Laboratories and IMPRIS, Seattle, WA, Abstract presented at USCAP 2005. Modern Pathology 2005; 18, suppl.1,pag 35A 12. D.O. Treaba, A.W. Hing, L.C. Goldstein, T.S. Barry, P. Kandalaft, C.B. Gilks, T.O. Nielsen and A.M. Gown, Clinical Research Division , PhenoPath Laboratories and IMPRIS, Seattle, WA, USA Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada, Abstract presented at USCAP 2005. Modern Pathology 2005; 18, suppl.1,pag 53A 13. S. Rossi1, L. Laurino1, A. Furlanetto1, S.Chinellato1, E. Orvieto1, F. Canal1, F. Facchetti2, A.P. Dei Tos1 1 Depart. Pathology, Hospital of Treviso, Italy, 2 Brescia University School of Medicine, Brescia, Italy, Am J Clin Pathol, 2005, Aug;124(2):295-302

https://usbio-images.r.worldssl.net/prodimages/5/P1001-37Q_1.jpg

Immunohistochemical analysis of paraffin-embedded human colon carcinoma, using p70 S6 Kinase (49D7) Rabbit mAb.